• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Soft­Bank bets $1.1B on Roivant CEO Vivek Ra­maswamy’s brash new biotech strat­e­gy

8 years ago
People
Financing

Melin­ta will beef up its an­tibi­otics pipeline af­ter a merg­er with trou­bled Cem­pra

8 years ago
Deals

Chi­na biotech bags a $57M round as it races to com­plete R&D, man­u­fac­tur­ing site

8 years ago
Financing
China

Try­ing to turn a new leaf, Valeant ‘block­buster’ can’t shed an R&D jinx

8 years ago
R&D

War­ring with ex-CEO, op­tions shrink­ing, Aeter­na Zen­taris turns to a strate­gic re­view

8 years ago
R&D

Aclaris bags St. Louis biotech for $20M; Pfiz­er in­vest­ing $100M in gene ther­a­py work

8 years ago
News Briefing

Sanofi be­lieves it’s still not too late to be­come a top play­er in can­cer drug mar­ket

8 years ago
R&D

Es­pe­ri­on shares bounce up on an ef­fec­tive triplet ap­proach to slash­ing LDL

8 years ago
R&D

Prep­ping for a rapid-fire launch, Kite Phar­ma gets a pass from FDA on axi-cel pan­el re­view

8 years ago
R&D

Roche sells off its strug­gling IL-13 drug le­brik­izum­ab in $1.4B Der­mi­ra deal

8 years ago
Pharma

Prep­ping for PhI­II can­cer study, Sel­l­as re­verse merges its way to a pub­lic list­ing

8 years ago
Pharma

Fi­bro­Gen shares rock­et up on pos­i­tive PhII da­ta in id­io­path­ic pul­monary fi­bro­sis

8 years ago
R&D

FDA slams Ver­nalis with 2nd CRL in 3 months; For­mer Shkre­li com­pa­ny Kalo­Bios changes name

8 years ago
News Briefing

Up­dat­ed: Acor­da shares surge as a big in­vestor push­es it to the auc­tion block

8 years ago
Financing

Mallinck­rodt bags late-stage in­fan­tile jaun­dice drug in $425M In­faCare buy­out deal

8 years ago
Deals

Zyner­ba goes in­to melt­down mode as cannabis-de­rived drug flops in PhII

8 years ago
R&D

A small, ground­break­ing car­dio study push­es MyoKar­dia to a piv­otal show­down — shares soar

8 years ago
R&D

GSK déjà vu: Time for a top-down switch as new CEO tries to con­quer old R&D demons

8 years ago
People
R&D

Gem­phire shares crater af­ter its LDL drug comes up short in PhI­Ib

8 years ago
R&D

Ju­ry finds Mar­tin Shkre­li guilty on 3 counts of se­cu­ri­ties fraud — and he's 'de­light­ed'

8 years ago
People

Big Phar­ma vet­er­ans at Pfiz­er, As­traZeneca join the great mi­gra­tion to biotech

8 years ago
Peer Review

Post-merg­er, In­da­lo rais­es $9M; Spark rais­ing $331M; No word on Shkre­li’s fate

8 years ago
News Briefing

Aeter­na Zen­taris claims it boot­ed CEO and then dis­cov­ered a plot to grab con­trol of its lead as­set

8 years ago
People

Eli Lil­ly’s new, $1B pain drug racks up an­oth­er promis­ing round of PhI­II pain da­ta

8 years ago
R&D
First page Previous page 1092109310941095109610971098 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.